載入中
NASDAQHealthcareBiotechnology
最新資料
US$4.45
−US$0.31 · -6.51%
Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary experimental drug, ARD-101, is an orally administered, gut-specific small molecule. It functions as an agonist, targeting particular bitter taste receptors found within the gut lumen. ARD-101 is currently undergoing a Phase III clinical trial for managing excessive hunger (hyperphagia) associated with Prader-Willi Syndrome. Additionally, it is in a Phase II trial for addressing hyperphagia linked to acquired hypothalamic obesity, often a result of craniopharyngioma treatments like surgery or radiation therapy. Aardvark Therapeutics is also advancing ARD-201, which is currently in Phase I clinical trials for the treatment of obesity. Established in 2017, the company is based in San Diego, California.
收盤時
US$4.45
−US$0.31 · -6.51%
盤後
US$4.45
US$0.00 · 0.00%
10月12日 下午4:26 ET
盤中時間採用ET。市場資料可能有所延遲。
Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary experimental drug, ARD-101, is an orally administered, gut-specific small molecule. It functions as an agonist, targeting particular bitter taste receptors found within the gut lumen. ARD-101 is currently undergoing a Phase III clinical trial for managing excessive hunger (hyperphagia) associated with Prader-Willi Syndrome. Additionally, it is in a Phase II trial for addressing hyperphagia linked to acquired hypothalamic obesity, often a result of craniopharyngioma treatments like surgery or radiation therapy. Aardvark Therapeutics is also advancing ARD-201, which is currently in Phase I clinical trials for the treatment of obesity. Established in 2017, the company is based in San Diego, California.
日內區間
目前US$4.45
52週區間
目前US$4.45
盤中時間採用ET。市場資料可能有所延遲。
Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary experimental drug, ARD-101, is an orally administered, gut-specific small molecule. It functions as an agonist, targeting particular bitter taste receptors found within the gut lumen. ARD-101 is currently undergoing a Phase III clinical trial for managing excessive hunger (hyperphagia) associated with Prader-Willi Syndrome. Additionally, it is in a Phase II trial for addressing hyperphagia linked to acquired hypothalamic obesity, often a result of craniopharyngioma treatments like surgery or radiation therapy. Aardvark Therapeutics is also advancing ARD-201, which is currently in Phase I clinical trials for the treatment of obesity. Established in 2017, the company is based in San Diego, California.
日內區間
目前US$4.45
52週區間
目前US$4.45
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 |
|---|---|---|---|---|
| 研究與開發 | 4893.6萬 USD | 1736.3萬 USD | 448萬 USD | 717.2萬 USD |
| 銷售、一般及管理費用 | 1378.9萬 USD | 530.5萬 USD | 217.3萬 USD | 270.2萬 USD |
| 營業費用 | 6272.5萬 USD | 2278.5萬 USD | 741.5萬 USD | 1136.3萬 USD |
| 利息收入 | 513.9萬 USD | 241.4萬 USD | 142.3萬 USD | 12萬 USD |
| 折舊和攤銷 | 3.6萬 USD | 1.6萬 USD | 9.7萬 USD | 11萬 USD |
| 營業利益 | −6272.5萬 USD | −2278.5萬 USD | −741.5萬 USD | −1136.3萬 USD |
| 淨利 | −5759.1萬 USD | −2058.8萬 USD | −720.8萬 USD | −1356.4萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$3.00
下跌空間 32.58%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI249.29萬0.00%2.3兆 USD0.03%US$381.57-0.10%
Vanguard Extended Market ETFVXF85.64萬0.00%954億 USD0.05%US$233.52-0.63%
iShares Biotechnology ETFIBB46.63萬0.00%108.2億 USD0.44%US$204.26-1.08%
iShares Micro-Cap ETFIWC19.07萬0.01%13.17億 USD0.60%US$181.66-0.73%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM11萬0.10%1.17億 USD0.73%US$15.8484-0.58%
Avantis U.S. Small Cap Equity ETFAVSC2.22萬—30.82億 USD0.25%US$69.97-0.01%
U.S. Vector Equity Portfolio ETF Class SharesDXUV1.07萬0.00%61.81億 USD0.26%US$68.32+0.06%
Invesco Nasdaq Biotechnology ETFIBBQ7639.80.01%1.12億 USD0.19%US$34.2482-1.07%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAvantis U.S. Small Cap Equity ETFAVSCU.S. Vector Equity Portfolio ETF Class SharesDXUVInvesco Nasdaq Biotechnology ETFIBBQAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
